Eiger BioPharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 3.21 million compared to USD 4.02 million a year ago. Net loss was USD 18.03 million compared to USD 27.11 million a year ago. Basic loss per share from continuing operations was USD 12.3 compared to USD 18.6 a year ago.
For the nine months, revenue was USD 11.97 million compared to USD 10.79 million a year ago. Net loss was USD 61.51 million compared to USD 71.64 million a year ago. Basic loss per share from continuing operations was USD 41.7 compared to USD 52.8001 a year ago.